144 results about "Clavulanic acid" patented technology

Polymers (i.e. polyesters, polyamides, polythioesters, polyanhydrides, or a mixture thereof) which degrade hydrolytically to provide a combination of a beta-lactam antibiotic (e.g., amoxicillin) and a beta-lactamase inhibitor (e.g., clavulanic acid) (or a pharmaceutically acceptable salt thereof) are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor (or a pharmaceutically acceptable salt thereof) to a host are also provided.

It is intended to provide a reagent composition for detecting beta-lactamase which contains 3-[2,4-dinitrostyryl]-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid or 7-[2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(2,4-dinitrostyryl)-3-cephem-4-carboxylic acid as a substrate for detecting beta-lactamase together with at least one beta-lactamase inhibitor selected from among clavulanic acid, aztreonam, ethylenediaminetetraacetic acid and cloxacillin and by which beta-lactamase can be quickly and easily identified at a high sensitivity. Moreover, a detection kit containing the above detection reagent composition and a method of detecting beta-lactamase comprising contacting a liquid specimen containing the subject to be analyzed with the above composition are provided.

The invention involves antibiotic compound recipe containing piperacillin, sulbactam or clavulanic acid, ion chelator which can inhibit the formation of particles chelator, the recipe can be further added in buffering ingredient as stability system, the characteristics of the recipe is that it can be prepared to stable pharmaceutical solutions, and with aminoglycoside antibiotics in the same container are re-prepared to drugs used for complex anti-microbial infection.

The present invention provides formulations comprising amoxicillin and clavulanate for reconstitution into an aqueous suspension incorporate low levels of carboxymethylcellulose sodium to stabilise the pH thereof.

The invention belongs to the technical field of pharmacy, and relates to a preparation method of clavulanic acid amine salt. The method comprises the following steps: (1) extraction of a clavulanic acid aqueous solution and concentration of extract liquor: acidizing the clavulanic acid aqueous solution, then adding a salting-out agent, and extracting by an organic solvent, thus obtaining the extract liquor containing clavulanic acid; nano-filtering and concentrating by using an organic solvent-resistant film, thus obtaining a clavulanic acid extraction concentrated solution; (2) preparation of the clavulanic acid amine salt: mixing the clavulanic acid extraction concentrated solution with an organic amine donor and a cosolvent, thus obtaining clavulanic acid amine salt crystals. The salting-out agent is introduced, and the extraction rate of the clavulanic acid is increased; the organic solvent-resistant roll film is innovatively adopted for nano-filtering and concentrating, so the energy consumption is lowered; the addition of the cosolvent can effectively reduce the content of various impurities in a final clavulanic acid amine salt product. Therefore, in the quality parameter aspects of the content, the impurities, light transmittance and the like, the clavulanic acid amine salt prepared by the preparation method is remarkably superior to clavulanic acid amine salt prepared by a conventional process.

The invention discloses an amoxicillin potassium clavulanate powder injection which is prepared from the following raw materials in percentage by weight: 10% of amoxicillin, 2.5% of potassium clavulanate, 4% of cosolvent and the balance of soluble filler. The invention also discloses a preparation method of the amoxicillin potassium clavulanate powder injection. The test proves that the amoxicillin potassium clavulanate powder injection disclosed by the invention has the characteristics of stability in storage, convenience in transportation, good water solubility and the like and greatly improves the curative effect of the amoxicillin and potassium clavulanate, thereby being a novel broad-spectrum and efficient special powder injection for animals.

An antibiotic composition of meloxine, which is composed of meloxine andª‰-lactamase inhibitor at the weight ratio of 1-10í†10-1 based on the amount of active acids. meloxine is in the form of the alkali salt of meloxine or in the form of its free acid and solubility promoter; theª‰-lactamase inhibitor is clavulanic acid or tazobactam or their derivatives. Besides mixing and preparing beforehand,the composition could be prepared by mixing meloxine andª‰-lactamase inhibitor proportionally in clinical applications, then is administered, ormeloxine andª‰-lactamase inhibitor are administered independently. meloxine andª‰-lactamase inhibitor are synergetic, which could solve the problem of meloxine resistance in clinical applications.

The invention provides a beta-cyclodextrin / amoxicillin inclusion compound medicinal composition which comprises amoxicillin and beta cyclodextrin by the weight ratio of 1:2.5-1:5. In a preferred embodiment, the composition also comprises clavulanate potassium, wherein the mass ratio of amoxicillin and clavulanate potassium is 14:1-2:1, the supplementary materials are selected from crystalline cellulose, maize starch, citric acid, talcum powder, sodium carboxymethylstarch, stearic acid, calcium stearate, magnesium stearate, amylopectin, lactose, mannitol, crosslinked povidone, talcum powder, polyethylene glycol 4000, and low substituted methylcellulose propylene glycol ether. The invention also discloses the preparing process.

The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and / or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and / or a combination thereof. The invention also relates to pharmaceutical compositions including (Z)-3-Carboxymethyl-7-(2-(2-furyl)-2-methoxyiminoacetylamino)-3-sefem-4-carboxylic acid which is named cefuroxime axetil or any pharmaceutically acceptable derivative thereof, and the use of these compositions in the treatment of bacterial infections. Lastly, the invention relates to pharmaceutical formulations including a third generation cephalosporin together with clavulanic acid and / or derivatives thereof as the active agents.

The invention discloses a method for purifying clavulanic acid from fermentation liquor. The method comprises the steps of performing ultrafiltration treatment on the fermentation liquor and removing solids and partial coloring matters in the fermentation liquor to obtain penetrating fluid A; performing first stage nanofiltration treatment on the penetrating fluid A and removing proteins and surplus coloring matters in the penetrating fluid A to obtain penetrating fluid B; performing second stage nanofiltration treatment on the penetrating fluid B and removing partial water in the penetrating fluid B to obtain intercepted concentrated liquor C; and performing extraction separation on the concentrated liquor C to prepare purification liquid of the clavulanic acid. Solid bodies, the proteins, sugars and the coloring matters in the fermentation liquor can be effectively removed through the ultrafiltration treatment and the first stage nanofiltration treatment, so that the concentrated liquor C can be easily layered in a subsequent extraction separation process, excessive emulsion can be avoided, high speed centrifugation treatment is not needed, and investment cost of equipment can be greatly reduced.

Plasmid with lat gene deletion of claviform streptomyces, its derivative and constructing method are disclosed. Upstream and downstream inducers are designed to in vitro amplify lat gene, constructing plasmid and derivative with single exchage and assembly, deletion mutating lat gene with influence on clavulanic acid yield, and constructing in colibacellus. The said plasmid contains a part of encoded lysine e-transaminase gene and duplication inducing points of plasmids of colibacillus and streptomyces, resistant selective marks of ambylan expressed in colibacillus and streptomyces, and moderate sensitive duplication sub-gene.

The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or Clavitesse™, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.